NCT05024968View on ClinicalTrials.gov

Sintilimab in Cancer of Unknown Primary

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 26, 2021

Primary Completion Date

April 3, 2025

Study Completion Date

April 3, 2025

Conditions
Cancer of Unknown Primary Site
Interventions
DRUG

Sintilimab

Given by IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT05024968 - Sintilimab in Cancer of Unknown Primary | Biotech Hunter | Biotech Hunter